Join our Newsletter
Browse by Category
-
Most Read This Week
- WHO reports wild poliovirus outbreak in Africa
- Study shows vitamin C kills drug-resistant strands of TB
- Agenus initiates enrollment in brain tumor vaccine trial
- Expert doubts CDC promotion of influenza vaccine
- Vical Incorporated announces results of herpes vaccine trial
- Swine-origin flu variant cases continue in U.S.
- Scientist map critical portion of anti-influenza antibody
- Boy dies from superbug infection at NIH hospital
- Progress made on new TB drug
Tags
Africa AIDS anthrax Avian flu Canada Cancer CDC Centers for Disease Control chicken pox China cholera Dengue fever Detection technology Ebola H1N1 H5N1 Hepatitis Hepatitis B HIV HPV Human papillomavirus immunization India Infectious disease Influenza Malaria Maryland Measles Medical Countermeasures meningitis MRSA Mumps News Pertussis pneumonia polio Preparedness research rotavirus Tuberculosis vaccine development West Nile virus whooping cough World Health Organization Yellow Fever
Tag Archives: Maryland
Second West Nile case reported in Boston
Health officials in Boston have reported that a 75-year-old man has become the second city resident to test positive for West Nile Virus this year. Read More »
Emergent BioSolutions’ CEO recognized as outstanding international business leader
ROCKVILLE, Md. Read More »
Cyto Pulse, Karolinska Institutet get clinical trial approval
Cyto Pulse Sciences announced approval from the Swedish Medical Products Agency to conduct a phase I clinical trial evaluating an HIV/DNA vaccine in collaboration with the Karolinska Institutet and the Swedish Institute for Infectious Disease Control. Read More »
Novavax, Rovi end flu vaccine development plan
TEL AVIV, Israel Read More »
More than 3 million doses of BioThrax delivered to HHS
Emergent BioSolutions Inc. that it has successfully completed the fourth-quarter 2006 deliveries of more than 3 million doses of BioThrax (Anthrax Vaccine Adsorbed) to the Department of Health and Human Services. Read More »
Emergent BioSolutions gets $24 million to develop anthrax monoclonal antibody
ROCKVILLE, Md. Read More »
HHS says proposal to provide anthrax vaccine ‘technically acceptable’
Emergent BioSolutions Inc. announced that the Department of Health and Human Services has informed the company that its proposal to provide a recombinant protective antigen anthrax vaccine (rPA) is technically acceptable. Read More »